Lawrence Steinman - 01 May 2026 Form 4 Insider Report for Pasithea Therapeutics Corp. (KTTA)

Reporting relationship: Director
Issuer ticker: KTTA
Reported as of: 01 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 May 2026, 16:42:04 UTC
Prior SEC filing: 01 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Lawarence Steinman

Key filing fact

Lawrence Steinman filed Form 4 for Pasithea Therapeutics Corp. (KTTA) on 05 May 2026.

Key facts

This page summarizes Lawrence Steinman's Form 4 filing for Pasithea Therapeutics Corp. (KTTA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 May 2026, 16:42.

Change

Previous filing in this sequence was filed on 01 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001132679 Primary reporting owner

STEINMAN LAWRENCE

Relationship: Director
Address: 1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Signature: /s/ Lawarence Steinman
Signature date: 05 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KTTA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +152,783
Change %
Price: $0.000000^*
Shares after: 152,783
Date: 01 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 152,783
Exercise price: $0.8410
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan).